Dr. Daniel Tietjen

Daniel Tietjen is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. His focus is on litigation and legal advice to national and international companies, particularly in all areas of pharmaceutical law, medical device law, unfair competition law and intellectual property law including trademark law.

CV

Since 2017 Lawyer, Taylor Wessing

2012 – 2017 Lawyer, Hogan Lovells International LLP

2009 – 2012 Legal counsel, Centre for Protection against Unfair Competition (Wettbewerbszentrale)

Carrière

Since 2017 Lawyer, Taylor Wessing

2012 – 2017 Lawyer, Hogan Lovells International LLP

2009 – 2012 Legal counsel, Centre for Protection against Unfair Competition (Wettbewerbszentrale)

Publications

Possible ban on the mail-order of prescription-only (Rx) medicinal products in Germany, Dr. Daniel Tietjen, March 2018
Software als Medizinprodukt, Dr. Daniel Tietjen, Zeitschrift für Stoffrecht Jahrgang 15, Ausgabe 1 (2018) pp. 19 - 21
Dynamische und personalisierte Preise: Welche lauterkeitsrechtlichen Schranken gelten für Unternehmen?, in: GRUR-Prax 2017, 546 (zusammen mit Dr. Benedikt F. Flöter)
„Das System des gemeinschaftsrechtlichen Staatshaftungsrechts“, Duncker & Humblot, Berlin, 2010
„Die Bedeutung der deutschen Richterprivilegien im System des gemeinschaftsrechtlichen Staatshaftungsrechts“, EWS 2007, 15

Langues étrangères

Prix et distinctions

JUVE Handbook 2024/2025

Featured

JUVE Handbook 2024/2025

JUVE Awards 2023

The Best Lawyers™ in Germany 2024

Experience

NORD Holding on the acquisition of Zentrum Gesundheit Group

NORD Holding, a leading private equity house, on the acquisition of the majority interest in Zentrum Gesundheit Group, a leading German group of ophthalmic surgery and diagnostic centres, from Waterland Private Equity. NORD Holding, together with the management and medical team, acquired a stake as a new partner and majority shareholder. In this deal the Taylor Wessing team again demonstrated its interdisciplinary expertise in the areas of healthcare M&A, regulatory and acquisition financing.

Press release

Dr. Oliver Kirschner

Dr. Oliver Klöck

Ulf Gosejacob

Maria Weiers

Dr. Anne Steinhardt

Christopher Peine

Dr. Michael Beyer, Dipl.-Volkswirt

Dr. Vanessa Christin Vollmar

Dr. Lars Hagen

Dr. Marco Hartmann-Rüppel, Dipl.-Volkswirt

Dr. Michael Brüggemann

Thanos Rammos, LL.M.

Dr. Daniel Tietjen

Actualités et publications récentes

View Daniel's insights

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

National penalties for breach of medical device advertising rules

10 décembre 2024

par plusieurs auteurs

Synapse - Life sciences advertising

Can medical devices be advertised on social media in Europe?

Advertising medical devices on social media in Europe is complex, requiring compliance with diverse national regulations and careful planning to avoid legal pitfalls.

10 décembre 2024

par plusieurs auteurs

1 de 4 Publications

Cliquer ici pour en savoir plus

Synapse - Life sciences advertising

Taking care around use of social media for medicines companies

Pharmaceutical companies must exercise caution when using social media for advertising in Europe. Compliance with diverse national laws, transparency in promotional activities, and careful planning are essential.

10 décembre 2024

par plusieurs auteurs

4 de 4 Publications

Cliquer ici pour en savoir plus

Dr. Daniel Tietjen

JUVE Handbook 2024/2025

Expertise

Services et Groupes

Secteurs